Stereotaxis, Inc. (STXS)

pvfund (< 20) Submitted: 9/25/07 1:45 PM : Start Price: $12.91 STXS Score: -35.45

STXS has FDA approval to perform the actual procedures in EP, AF and has a competitive advantage over its rival HNSN because 66 systems have been installed and 10000 procedures have been performed with glowing results. Revs are lumpy as installation of Niobe systems require stripping down cath labs and reinforcing magnetic sheilds. That would be a capex and hospitals which ave installed clearly saw the value.





HNSN has been performing better as a stock and not as a company and I would attribute that to the wallstreet's regards to the founders ISRG pedigree. HNSN has not been able to get FDA approval to perform any medical procedures than for mapping purposes of the heart. If you dig deeper you could find that they have been able to form partnerships and pretty much give away their systems to show some semblence of acceptance. I will trust in their viability once FDA approves even a single procedure.

Report this Post Replies: 0 | Reply